Ledipasvir/sofosbuvir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ledipasvir/sofosbuvir" in English language version.

refsWebsite

Global rank English rank

20nih.gov

4^th place

10doi.org

2^nd place

4web.archive.org

1^st place

3tga.gov.au

3,984^th place

2,622^nd place

2drugs.com

399^th place

333^rd place

2europa.eu

68^th place

117^th place

2handle.net

102^nd place

76^th place

2natap.org

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1semanticscholar.org

11^th place

8^th place

1worldcat.org

5^th place

1fda.gov

447^th place

338^th place

1canada.ca

1,712^th place

1,063^rd place

1businesswire.com

615^th place

407^th place

1gilead.com

low place

1harvard.edu

18^th place

17^th place

1drugbank.ca

4,294^th place

6,357^th place

1kumc.edu

low place

businesswire.com

"Health Canada Issues Notice of Compliance for Gilead's Harvoni (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C" (Press release). Gilead Sciences, Inc. 16 October 2014. Retrieved 29 August 2020 – via Business Wire.

canada.ca

health-products.canada.ca

"Notice of Compliance (NOC) online query". 25 August 2010.

doi.org

Keating GM (April 2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–685. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (January 2015). "Global distribution and prevalence of hepatitis C virus genotypes". Hepatology. 61 (1): 77–87. doi:10.1002/hep.27259. PMC 4303918. PMID 25069599.
Issur M, Götte M (November 2014). "Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding". Viruses. 6 (11): 4227–4241. doi:10.3390/v6114227. PMC 4246218. PMID 25384189.
Gao M (October 2013). "Antiviral activity and resistance of HCV NS5A replication complex inhibitors". Current Opinion in Virology. 3 (5): 514–520. doi:10.1016/j.coviro.2013.06.014. PMID 23896281.
Vermehren J, Sarrazin C (August 2012). "The role of resistance in HCV treatment". Best Practice & Research. Clinical Gastroenterology. 26 (4): 487–503. doi:10.1016/j.bpg.2012.09.011. PMID 23199507.
Gong G, Waris G, Tanveer R, Siddiqui A (August 2001). "Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B". Proceedings of the National Academy of Sciences of the United States of America. 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. doi:10.1073/pnas.171311298. PMC 55498. PMID 11481452.
Lin MV, Chung R (March 2014). "Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment". Clinical Liver Disease. 3 (3): 65–68. doi:10.1002/cld.332. PMC 6448702. PMID 30992888.
Pawlotsky JM (August 2013). "NS5A inhibitors in the treatment of hepatitis C". Journal of Hepatology. 59 (2): 375–382. doi:10.1016/j.jhep.2013.03.030. PMID 23567084.
Cada DJ, Baker DE, Bindler RJ (March 2015). "Ledipasvir/Sofosbuvir". Hospital Pharmacy. 50 (3): 224–234. doi:10.1310/hpj5003-224. PMC 4567193. PMID 26405313.
Elkady EF, Aboelwafa AA (September 2016). "A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma". Journal of AOAC International. 99 (5): 1252–1259. doi:10.5740/jaoacint.16-0021. PMID 27480956.

drugbank.ca

"Sofosbuvir". www.drugbank.ca. Retrieved 2018-03-23.

drugs.com

"Ledipasvir / sofosbuvir (Harvoni) Use During Pregnancy". Drugs.com. 28 October 2019. Retrieved 17 March 2020.
"Ledipasvir and Sofosbuvir". The American Society of Health-System Pharmacists. Archived from the original on 25 December 2016. Retrieved 8 December 2016.

europa.eu

ema.europa.eu

"Harvoni EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 29 August 2020.
"Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 February 2020.

fda.gov

accessdata.fda.gov

"Drug Approval Package:Harvoni (ledipasvir and sofosbuvir) Tablets NDA 205834". U.S. Food and Drug Administration (FDA). 3 November 2014. Retrieved 29 August 2020.
"APPLICATION NUMBER: 205834Orig1s000" (PDF) (Summary Review). Center for Drug Evaluation and Research.

gilead.com

"Harvoni Presribing Information" (PDF). Gilead Sciences. March 2020. Retrieved 2018-02-21.

handle.net

hdl.handle.net

World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. pp. 69–70. hdl:10665/189763. ISBN 9789241209946. ISSN 0512-3054. WHO technical report series;994.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Gong G, Waris G, Tanveer R, Siddiqui A (August 2001). "Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B". Proceedings of the National Academy of Sciences of the United States of America. 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. doi:10.1073/pnas.171311298. PMC 55498. PMID 11481452.

kumc.edu

"Pharmacology: Basic Pharmacology, ANS, Endocrine". www.kumc.edu. Archived from the original on 2018-01-15. Retrieved 2018-03-23.

medicines.org.uk

"Harvoni 90 mg/400 mg film-coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. December 2016. Archived from the original on 27 October 2016. Retrieved 4 February 2017.

natap.org

"Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals". www.natap.org. Retrieved 2018-02-22.
"Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir". www.natap.org. Retrieved 2018-02-22.

nih.gov

pubmed.ncbi.nlm.nih.gov

Keating GM (April 2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–685. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (January 2015). "Global distribution and prevalence of hepatitis C virus genotypes". Hepatology. 61 (1): 77–87. doi:10.1002/hep.27259. PMC 4303918. PMID 25069599.
"Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence". Rapid Response Service. Canadian Agency for Drugs and Technologies in Health. 16 January 2015. PMID 25674658. Archived from the original on 5 November 2017.
Issur M, Götte M (November 2014). "Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding". Viruses. 6 (11): 4227–4241. doi:10.3390/v6114227. PMC 4246218. PMID 25384189.
Gritsenko D, Hughes G (April 2015). "Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection". P & T. 40 (4): 256–276. PMC 4378517. PMID 25859119.
Gao M (October 2013). "Antiviral activity and resistance of HCV NS5A replication complex inhibitors". Current Opinion in Virology. 3 (5): 514–520. doi:10.1016/j.coviro.2013.06.014. PMID 23896281.
Vermehren J, Sarrazin C (August 2012). "The role of resistance in HCV treatment". Best Practice & Research. Clinical Gastroenterology. 26 (4): 487–503. doi:10.1016/j.bpg.2012.09.011. PMID 23199507.
Gong G, Waris G, Tanveer R, Siddiqui A (August 2001). "Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B". Proceedings of the National Academy of Sciences of the United States of America. 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. doi:10.1073/pnas.171311298. PMC 55498. PMID 11481452.
Lin MV, Chung R (March 2014). "Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment". Clinical Liver Disease. 3 (3): 65–68. doi:10.1002/cld.332. PMC 6448702. PMID 30992888.
Pawlotsky JM (August 2013). "NS5A inhibitors in the treatment of hepatitis C". Journal of Hepatology. 59 (2): 375–382. doi:10.1016/j.jhep.2013.03.030. PMID 23567084.
Cada DJ, Baker DE, Bindler RJ (March 2015). "Ledipasvir/Sofosbuvir". Hospital Pharmacy. 50 (3): 224–234. doi:10.1310/hpj5003-224. PMC 4567193. PMID 26405313.
Elkady EF, Aboelwafa AA (September 2016). "A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma". Journal of AOAC International. 99 (5): 1252–1259. doi:10.5740/jaoacint.16-0021. PMID 27480956.

ncbi.nlm.nih.gov

Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (January 2015). "Global distribution and prevalence of hepatitis C virus genotypes". Hepatology. 61 (1): 77–87. doi:10.1002/hep.27259. PMC 4303918. PMID 25069599.
"Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence". Rapid Response Service. Canadian Agency for Drugs and Technologies in Health. 16 January 2015. PMID 25674658. Archived from the original on 5 November 2017.
Issur M, Götte M (November 2014). "Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding". Viruses. 6 (11): 4227–4241. doi:10.3390/v6114227. PMC 4246218. PMID 25384189.
Gritsenko D, Hughes G (April 2015). "Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection". P & T. 40 (4): 256–276. PMC 4378517. PMID 25859119.
Gong G, Waris G, Tanveer R, Siddiqui A (August 2001). "Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B". Proceedings of the National Academy of Sciences of the United States of America. 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. doi:10.1073/pnas.171311298. PMC 55498. PMID 11481452.
Lin MV, Chung R (March 2014). "Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment". Clinical Liver Disease. 3 (3): 65–68. doi:10.1002/cld.332. PMC 6448702. PMID 30992888.
Cada DJ, Baker DE, Bindler RJ (March 2015). "Ledipasvir/Sofosbuvir". Hospital Pharmacy. 50 (3): 224–234. doi:10.1310/hpj5003-224. PMC 4567193. PMID 26405313.

dailymed.nlm.nih.gov

"Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir pellet". DailyMed. 16 March 2020. Retrieved 29 August 2020.

semanticscholar.org

api.semanticscholar.org

Keating GM (April 2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–685. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.

tga.gov.au

"AusPAR: Ledipasvir / Sofosbuvir". Therapeutic Goods Administration (TGA). 29 October 2015. Retrieved 29 August 2020.
"AusPAR: Sofosbuvir / Ledipasvir". Therapeutic Goods Administration (TGA). 16 November 2017. Retrieved 29 August 2020.
"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

"Harvoni 90 mg/400 mg film-coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. December 2016. Archived from the original on 27 October 2016. Retrieved 4 February 2017.
"Ledipasvir and Sofosbuvir". The American Society of Health-System Pharmacists. Archived from the original on 25 December 2016. Retrieved 8 December 2016.
"Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence". Rapid Response Service. Canadian Agency for Drugs and Technologies in Health. 16 January 2015. PMID 25674658. Archived from the original on 5 November 2017.
"Pharmacology: Basic Pharmacology, ANS, Endocrine". www.kumc.edu. Archived from the original on 2018-01-15. Retrieved 2018-03-23.

worldcat.org

search.worldcat.org

World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. pp. 69–70. hdl:10665/189763. ISBN 9789241209946. ISSN 0512-3054. WHO technical report series;994.